Glenmark Pharma reports revenue growth of 13.9% and EBITDA growth of 30.8% YoY for Q3 FY 2021-22

Glenmark Pharmaceuticals Limited (Glenmark), a global innovation-driven pharmaceutical company, today announced its financial results for the third quarter ende

Related Keywords

Mumbai ,Maharashtra ,India ,Americanorth America ,Glenn Saldanha ,Latin Americaglenmark ,Latin Americancaribbean ,Europeglenmark Europe ,Glenmark Life Sciences ,Glenmark Pharmaceuticals Limited ,Company Rankings ,Glenmark Pharmaceuticals Ltd ,Chairmanmanaging Director ,Glenmark Pharmaceuticals ,Glenmark Europe ,Generics Bulletin ,Dow Jones Sustainability Index ,Corporate Sustainability ,Breaking International News ,Lobally ,Global Innovation ,Third ,Quarter ,Revious ,Pharmaceuticals ,Decline ,Glenmark Life ,